+

WO2008002165A3 - Procédé, dosage et coffret pour la prédiction et le traitement d'un sujet humain infecté par un virus - Google Patents

Procédé, dosage et coffret pour la prédiction et le traitement d'un sujet humain infecté par un virus Download PDF

Info

Publication number
WO2008002165A3
WO2008002165A3 PCT/PL2007/000044 PL2007000044W WO2008002165A3 WO 2008002165 A3 WO2008002165 A3 WO 2008002165A3 PL 2007000044 W PL2007000044 W PL 2007000044W WO 2008002165 A3 WO2008002165 A3 WO 2008002165A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
human subject
virus
prediction
assay
Prior art date
Application number
PCT/PL2007/000044
Other languages
English (en)
Other versions
WO2008002165A2 (fr
Inventor
Krzysztof Kucharczyk
Radoslaw Kaczanowski
Original Assignee
Krzysztof Kucharczyk
Radoslaw Kaczanowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krzysztof Kucharczyk, Radoslaw Kaczanowski filed Critical Krzysztof Kucharczyk
Publication of WO2008002165A2 publication Critical patent/WO2008002165A2/fr
Publication of WO2008002165A3 publication Critical patent/WO2008002165A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés et des réactifs pour déterminer la diversité de quasi-espèces virales et le nombre des différents variants viraux présents dans l'échantillon, lesquels procédés et réactifs sont utiles pour prédire la réponse à un traitement chez l'humain. La présente invention se fonde sur la découverte du fait que, chez un sujet humain infecté par un virus, on constate une association significative entre le changement du nombre de quasi-espèces virales différentes et leur diversité génétique et polypeptidique, et la réponse du sujet humain infecté au traitement dans les premières semaines de traitement. De façon spécifique, la probabilité d'une réponse virologique prolongée à un traitement comportant un interféron est supérieure chez les sujets présentant un nombre de sous-espèces virales différentes et une diversité polypeptidique moindre.
PCT/PL2007/000044 2006-06-30 2007-06-30 Procédé, dosage et coffret pour la prédiction et le traitement d'un sujet humain infecté par un virus WO2008002165A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81788806P 2006-06-30 2006-06-30
US60/817,888 2006-06-30

Publications (2)

Publication Number Publication Date
WO2008002165A2 WO2008002165A2 (fr) 2008-01-03
WO2008002165A3 true WO2008002165A3 (fr) 2008-05-29

Family

ID=38727463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2007/000044 WO2008002165A2 (fr) 2006-06-30 2007-06-30 Procédé, dosage et coffret pour la prédiction et le traitement d'un sujet humain infecté par un virus

Country Status (1)

Country Link
WO (1) WO2008002165A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2342363B1 (fr) * 2008-10-06 2015-06-10 Janssen Diagnostics BVBA Procédé pour déterminer des mutations de résistance aux médicaments dans l'une quelconque des régions protéiques non structurales ns3 à ns5b du virus de l'hépatite c (vhc) pour les génotypes 1 à 6
AU2013205064B2 (en) 2012-06-04 2015-07-30 Gen-Probe Incorporated Compositions and Methods for Amplifying and Characterizing HCV Nucleic Acid
EP2754450A1 (fr) 2013-01-11 2014-07-16 Österreichische Akademie der Wissenschaften Peptides dérivés de la Lactoferricine
WO2024223883A1 (fr) 2023-04-26 2024-10-31 Karl-Franzens-Universität Graz Peptides pour le traitement du cancer
WO2024223887A1 (fr) 2023-04-26 2024-10-31 Karl-Franzens-Universität Graz Peptides pour thérapie antimicrobienne

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039487A1 (fr) * 1997-03-05 1998-09-11 Ribogene, Inc. Nouveaux procedes de criblage permettant l'identification d'agents inhibant de maniere selective la replication du virus de l'hepatite c

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039487A1 (fr) * 1997-03-05 1998-09-11 Ribogene, Inc. Nouveaux procedes de criblage permettant l'identification d'agents inhibant de maniere selective la replication du virus de l'hepatite c

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ENOMOTO N ET AL: "COMPARISON OF FULL-LENGTH SEQUENCES OF INTERFERON-SENSITIVE AND RESISTANT HEPATITIS C VIRUS 1B. SENSITIVITY TO INTERFERON IS CONFERRED BY AMINO ACID SUBSTITUTIONS IN THE NS5A REGION", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 96, no. 1, 1 July 1995 (1995-07-01), pages 224 - 230, XP000196704, ISSN: 0021-9738 *
FARCI P ET AL: "THE OUTCOME OF ACUTE HEPATITIS C PREDICTED BY THE EVOLUTION OF THE VIRAL QUASISPECIES", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 288, 14 April 2000 (2000-04-14), pages 339 - 344, XP001183298, ISSN: 0036-8075 *
FARCI PATRIZIA ET AL: "Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 5, 5 March 2002 (2002-03-05), pages 3081 - 3086, XP002474017, ISSN: 0027-8424 *
OKADA S ET AL: "THE DEGREE OF VARIABILITY IN THE AMINO TERMINAL REGION OF THE E2/NS1 PROTEIN OF HEPATITIS C VIRUS CORRELATES WITH RESPONSIVENESS TO INTERFERON THERAPY IN VIREMIC PATIENTS", HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 16, no. 3, September 1992 (1992-09-01), pages 619 - 624, XP001018408, ISSN: 0270-9139 *

Also Published As

Publication number Publication date
WO2008002165A2 (fr) 2008-01-03

Similar Documents

Publication Publication Date Title
Chen et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection
Paolucci et al. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients
Lange et al. IL28B single nucleotide polymorphisms in the treatment of hepatitis C
WO2008002165A3 (fr) Procédé, dosage et coffret pour la prédiction et le traitement d'un sujet humain infecté par un virus
WO2008060651A3 (fr) Sparc et procédés d'utilisation de celui-ci
Vermehren et al. Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection
WO2006110589A8 (fr) Gammaretrovirus associe au cancer
Lee et al. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4
Jung et al. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans
Covolo et al. The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection
WO2006110748A3 (fr) Gene de reponse au complement 32 (rgc-32) lors d'une maladie
WO2008058238A3 (fr) Variations de séquences du gène du récepteur a1 et a3 de l'adénosine pour prédire l'évolution de la maladie et le résultat thérapeutique
Huang et al. Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype
ATE374838T1 (de) Nukleotidsequenzvariation im gen ns5a als marker
Bagci et al. The investigation of host genetic variants of toll-like receptor 7 and 8 in COVID-19
Hwang et al. Implications of rapid virological response in hepatitis C therapy in the US veteran population
WO2005100611A3 (fr) Detection d'acide nucleique viral et methode pour une transcription inverse d'arn
WO2006022619A3 (fr) Methodes d'identification des risques de diabete de type ii et son traitement
WO2005118403A3 (fr) Procedes pour detecter l'expression genique dans des cellules du sang peripherique et utilisations de ces procedes
WO2005115459A3 (fr) Activite antivirale d'un anticorps monoclonal anti-thymidine kinase
RU2012122637A (ru) Биомаркеры для прогнозирования быстрого ответа на лечение гепатита с
Hoffmann et al. No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
WO2006012356A3 (fr) Procedes destines a determiner le risque de developpement d'un comportement de fumeur regulier
Dietz et al. Investigation of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy
WO2005055812A3 (fr) Biomarqueurs seriques de la maladie de chagas

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07747753

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07747753

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载